Avalyn Pharma
Update in progressAVLN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Avalyn Pharma Inc. is a clinical‑stage biopharmaceutical company developing inhaled medicines aimed at rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. It delivers inhaled formulations of oral drugs directly to the lungs. The pipeline centers on pulmonary fibrosis, with AP01 and AP02 being inhaled pirfenidone and nintedanib, AP03 a fixed-dose inhaled combination. Formerly Genoa Pharmaceuticals, renamed in 2017. Established 2011, based in Boston.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.24
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMs. Lyn Baranowski
- Founded2011
- Employees55
- Websitewww.avalynpharma.com